Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity

Hamano, Hirofumi; Ikeda, Yasumasa; Goda, Mitsuhiro; Fukushima, Keijo; Kishi, Seiji; Chuma, Masayuki; Yamashita, Michiko; Niimura, Takahiro; Takechi, Kenshi; Imanishi, Masaki; Zamami, Yoshito; Horinouchi, Yuya; Izawa‐Ishizawa, Yuki; Miyamoto, Licht; Ishizawa, Keisuke; Fujino, Hiromichi; Takahashi, Toshiaki; Aihara, Ken-ichi; Tsuchiya, Koichiro

doi:10.1016/j.kint.2020.10.041

Cited by 37 publications

(23 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 The most common AE of cisplatin is gastrointestinal reaction, and repeated use aggravates nephrotoxicity. 27 Raltitrexed is a fluorouracil analog, and its efficacy in advanced colorectal cancer has been confirmed. Its main mechanism is that reduced folate methotrexate is metabolized by intracellular folylpolyglutamate synthase to produce a series of polyglutamate compounds with stronger inhibition of thymidylate synthetase than raltitrexed, which can produce antitumor effects by inhibiting cell DNA synthesis.…”

Section: Adverse Eventsmentioning

confidence: 99%

Efficacy and safety of raltitrexed‐based transcatheter arterial chemoembolization for intermediate and advanced hepatocellular carcinoma: A multicenter real‐world study

Sun

et al. 2021

Hepatology Research

View full text Add to dashboard Cite

Aim: This study aimed to evaluate efficacy and safety of raltitrexed-based transcatheter arterial chemoembolization (TACE) for intermediate and advanced hepatocellular carcinoma (HCC) using real-world evidence.Methods: All eligible HCC cases were collected from multiple centers in Chongqing, China, from January 2013 to December 2018 and divided into the raltitrexed group (raltitrexed + lobaplatin + pirarubicin) and control group (lobaplatin + pirarubicin).Propensity score matching (PSM) with a 1:1 ratio was used to eliminate the imbalance of potential confounding factors between groups. The primary end-point was overall survival (OS) and the secondary end-points were progression-free survival (PFS) and disease control rate. Results:The median follow-up period for patients in the raltitrexed and control groups was 8.7 and 5.9 months, respectively. After PSM, median OS was 10.0 months in the raltitrexed group and 7.0 months in the control group (p = 0.002). The 6-month, 1-year, and 2-year OS rates of the raltitrexed group were significantly higher than those of the control group (78.2% vs. 60.9%, p = 0.010; 43.5% vs. 22.8%, p = 0.030; and 17.4% vs. 2.2% p = 0.001, respectively). Multivariate analysis of these propensity score-matched HCC patients revealed treatment, age, tumor size, lipiodol accumulation, and the number of TACE cycles as independent predictors of OS (all p < 0.05). The disease control rate of the raltitrexed and control groups was 87.4% and 65.8%, respectively (p < 0.001). Conclusions:Raltitrexed-based TACE can prolong the OS of patients with intermediate and advanced HCC in a real-world clinical setting, and is safe and tolerable.

show abstract

Section: Adverse Eventsmentioning

confidence: 99%

Efficacy and safety of raltitrexed‐based transcatheter arterial chemoembolization for intermediate and advanced hepatocellular carcinoma: A multicenter real‐world study

Sun

et al. 2021

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…Using the FAERS database, Hamano et al evaluated the efficacy of diphenhydramine, an antiallergic drug, in preventing cisplatin-induced kidney toxicity ( Hamano et al, 2021 ). They reported that the administration of diphenhydramine in a mouse model of cisplatin-associated renal injury improved the characteristics of renal damage (which included worsening renal function, histopathological changes, elevated inflammatory cytokines, and increased oxidative stress and apoptosis), whereas the histamine knockout mice did not show the same effects.…”

Section: Use Of Pharmacoepidemiology In Drug Repositioningmentioning

confidence: 99%

Drug-Repositioning Approaches Based on Medical and Life Science Databases

et al. 2021

Self Cite

View full text Add to dashboard Cite

Drug repositioning is a drug discovery strategy in which an existing drug is utilized as a therapeutic agent for a different disease. As information regarding the safety, pharmacokinetics, and formulation of existing drugs is already available, the cost and time required for drug development is reduced. Conventional drug repositioning has been dominated by a method involving the search for candidate drugs that act on the target molecules of an organism in a diseased state through basic research. However, recently, information hosted on medical information and life science databases have been used in translational research to bridge the gap between basic research in drug repositioning and clinical application. Here, we review an example of drug repositioning wherein candidate drugs were found and their mechanisms of action against a novel therapeutic target were identified via a basic research method that combines the findings retrieved from various medical and life science databases.

show abstract

“…Cisplatin inhibits DNA function and cell mitosis ( Hamano et al, 2021 ). Cisplatin has a wide antitumor spectrum and is used in the treatment of head and neck squamous cell carcinoma, ovarian cancer, embryonic cancer, lung cancer, and thyroid cancer ( Fang et al, 2021 ; Prayuenyong et al, 2021 ).…”

Section: Effects and Reverse Function Of Multidrug Resistance To Chemotherapeutic Agentsmentioning

confidence: 99%

Tetramethylpyrazine: A Review of Its Antitumor Potential and Mechanisms

Yang

Dai

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer remains a major public health threat. The mitigation of the associated morbidity and mortality remains a major research focus. From a molecular biological perspective, cancer is defined as uncontrolled cell division and abnormal cell growth caused by various gene mutations. Therefore, there remains an urgent need to develop safe and effective antitumor drugs. The antitumor effect of plant extracts, which are characterized by relatively low toxicity and adverse effect, has attracted significant attention. For example, increasing attention has been paid to the antitumor effects of tetramethylpyrazine (TMP), the active component of the Chinese medicine Chuanqiong, which can affect tumor cell proliferation, apoptosis, invasion, metastasis, and angiogenesis, as well as reverse chemotherapeutic resistance in neoplasms, thereby triggering antitumor effects. Moreover, TMP can be used in combination with chemotherapeutic agents to enhance their effects and reduce the side effect associated with chemotherapy. Herein, we review the antitumor effects of TMP to provide a theoretical basis and foundation for the further exploration of its underlying antitumor mechanisms and promoting its clinical application.

show abstract

Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity

Cited by 37 publications

References 43 publications

Efficacy and safety of raltitrexed‐based transcatheter arterial chemoembolization for intermediate and advanced hepatocellular carcinoma: A multicenter real‐world study

Efficacy and safety of raltitrexed‐based transcatheter arterial chemoembolization for intermediate and advanced hepatocellular carcinoma: A multicenter real‐world study

Drug-Repositioning Approaches Based on Medical and Life Science Databases

Tetramethylpyrazine: A Review of Its Antitumor Potential and Mechanisms

Contact Info

Product

Resources

About